EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back

Annapaola Mariniello, Maxime Borgeaud, Marc Weiner, Daniele Frisone, Floryane Kim, Alfredo Addeo

BioDrugs · 2025-03 · 39 (2) · 215-235

DOI: 10.1007/s40259-024-00700-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BioDrugs, online erschienen am 15.02.2025. Verfasst von Annapaola Mariniello und 5 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, University Hospital Geneva, rue Perret-Gentil 4, 1205, Geneva, Switzerland. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Drug Resistance, Neoplasm, Lung Neoplasms. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Geneva.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy with checkpoint inhibitors has become the cornerstone of systemic treatment for non-oncogene addicted non-small-cell lung cancer. Despite its pivotal role, a significant proportion of patients-approximately 70-85%-either exhibit primary resistance to PD-1 blockade or develop acquired resistance following an initial benefit, even in combination with chemotherapy and/or anti-CTLA-4 agents. The phenomenon of primary and acquired resistance to immunotherapy represents a critical clinical challenge, largely based on our incomplete understanding of the mechanisms of action of immunotherapy, and the resulting lack of accurate predictive biomarkers. Here, we review the definitions and explore the proposed mechanisms of primary and acquired resistance, including those related to the tumor microenvironment, systemic factors, and intrinsic tumor characteristics. We also discuss translational data on adaptive changes within tumor cells and the immune infiltrate following exposure to checkpoint inhibitors. Lastly, we offer a comprehensive overview of current and emerging therapeutic strategies designed to prevent primary resistance and counteract acquired resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsDrug Resistance, NeoplasmLung NeoplasmsImmunotherapyHumansTumor MicroenvironmentProgrammed Cell Death 1 ReceptorAnimals

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Oncology Department, University Hospital Geneva, rue Perret-Gentil 4, 1205, Geneva, Switzerland.
  • Oncology Department, University Hospital Geneva, rue Perret-Gentil 4, 1205, Geneva, Switzerland. alfredo.addeo@hug.ch.

Förderung

  • University of Geneva

Zitieren

APA

Mariniello, A., Borgeaud, M., Weiner, M., Frisone, D., Kim, F., & Addeo, A. (2025). Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back. BioDrugs, 39(2), 215-235. https://doi.org/10.1007/s40259-024-00700-2

Vancouver

Mariniello A, Borgeaud M, Weiner M, Frisone D, Kim F, Addeo A. Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back. BioDrugs. 2025;39(2):215-235. doi:10.1007/s40259-024-00700-2

BibTeX
@article{Mariniello2025,
  author = {Mariniello, Annapaola and Borgeaud, Maxime and Weiner, Marc and Frisone, Daniele and Kim, Floryane and Addeo, Alfredo},
  title = {Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back},
  journal = {BioDrugs},
  year = {2025},
  volume = {39},
  number = {2},
  pages = {215--235},
  doi = {10.1007/s40259-024-00700-2}
}
Kostenlos starten →